• O-GlcNAcylation Regulates OTX2 Proteostasis and Solubility

  2026-05-20

  Wulff-Fuentes et al. reveal that O-GlcNAcylation of the transcription factor OTX2 regulates its stability by limiting aggregate formation and promoting interactions with molecular chaperones. These findings offer mechanistic insight into how nutrient-sensitive post-translational modifications control protein homeostasis in development and disease.

• Dabigatran Etexilate: Direct Thrombin Inhibitor for Anticoag

  2026-05-19

  Dabigatran etexilate is a potent direct thrombin inhibitor used in anticoagulant and atrial fibrillation research. Its oral prodrug form offers rapid and predictable anticoagulation by selectively inhibiting thrombin, with extensive clinical validation for stroke and VTE prevention. APExBIO provides high-purity Dabigatran etexilate (SKU A8381) for reproducible laboratory and translational workflows.

• Chloroquine Diphosphate: Mechanisms, Benchmarks, and Researc

  2026-05-19

  Chloroquine diphosphate is a validated autophagy modulator and TLR7/TLR9 inhibitor, widely used in cancer and immunology research. Its precise mechanism includes cell cycle arrest and enhancement of chemotherapy sensitization, with robust, dose-dependent IC50 data. Protocols and limitations are clarified to maximize translational value.

• Biotin Azide: Precision Bio-Orthogonal Labeling for Protein

  2026-05-18

  Biotin Azide enables high-specificity, click chemistry-based labeling of alkynylated biomolecules, streamlining affinity purification and detection workflows. Its robust performance in aqueous, biologically compatible conditions makes it indispensable for dissecting lipid-mediated signaling and protein interactions in modern molecular biology.

• CD44-Driven Metabolic Rewiring in IDH1-Mutant Leukemia

  2026-05-18

  This study reveals that CD44 upregulation in IDH-mutant leukemia orchestrates a metabolic switch, sustaining NADPH production and oncometabolite (R)-2-hydroxyglutarate accumulation. Targeting this CD44-mediated pathway, especially in combination with IDH1 inhibition, may overcome resistance mechanisms and improve therapeutic outcomes in acute myeloid leukemia.

• Gramine: Applied Protocols for Ferroptosis in TNBC Research

  2026-05-17

  Gramine (1-(1H-indol-3-yl)-N,N-dimethylmethanamine) is transforming triple-negative breast cancer (TNBC) research by enabling robust ferroptosis assays via CUL3–MTDH axis targeting. Learn how APExBIO’s high-purity Gramine empowers reproducible workflows, troubleshooting, and advanced mechanistic studies in cancer biology.

• Engineered ClbS Bacteria Neutralize Gut Genotoxins In Situ

  2026-05-16

  This study introduces a novel strategy for in situ neutralization of the genotoxic metabolite colibactin in the gut by displaying the colibactin-inactivating enzyme ClbS on engineered bacteria. The approach outperforms previous methods in reducing DNA damage and tumorigenesis in mouse models, offering new translational potential for microbial metabolite modulation.

• A-1210477: Guiding Translational Progress in MCL-1 Targeting

  2026-05-15

  This thought-leadership article explores how the MCL-1 inhibitor A-1210477 empowers translational researchers to dissect apoptosis mechanisms in cancer, with actionable guidance on experimental design, protocol parameters, and clinical relevance. Drawing from recent literature and workflow best practices, the piece highlights the scientific rationale, validation strategies, and forward-looking implications for targeting MCL-1 in oncology.

• Catalpol in Translational Research: Protocols and Optimizati

  2026-05-15

  Catalpol’s multi-pathway activity enables robust, reproducible modeling in neuroprotection, osteoporosis, and liver fibrosis studies. This article delivers advanced workflow guidance, real-world troubleshooting, and actionable insights for maximizing Catalpol’s translational power across disease models.

• GS-441524: Prodrug Conversion Insights and Informed Assay De

  2026-05-14

  Explore GS-441524’s unique prodrug activation, solubility, and pharmacokinetics in antiviral research. This article provides advanced insights on GS-441524 prodrug conversion, informed by the latest LC–MS/MS studies and practical assay recommendations.

• PtrbZIP12 Phosphorylation Drives Drought Tolerance in Poplar

  2026-05-14

  This study demonstrates that the bZIP transcription factor PtrbZIP12 enhances drought resistance in Populus trichocarpa by directly activating stress-responsive genes through phosphorylation-dependent mechanisms. The findings clarify how post-translational modification of PtrbZIP12 orchestrates gene regulation under drought, illuminating new molecular targets for plant stress adaptation research.

• Gramine as a Precision Tool for Targeted Ferroptosis Pathway

  2026-05-13

  Explore how Gramine (1-(1H-indol-3-yl)-N,N-dimethylmethanamine) advances ferroptosis pathway mapping in triple-negative breast cancer. Uncover nuanced mechanistic insights, optimized assay parameters, and practical research implications.

• Phosphatase Inhibitor Cocktail: Precision in Phosphorylation

  2026-05-13

  APExBIO’s Phosphatase Inhibitor Cocktail (2 Tubes, 100X) offers dual-phase protection of protein phosphorylation, supporting reproducible results in advanced immunoblotting and kinase activity assays. Its unique two-tube design ensures both serine/threonine and tyrosine phosphatase inhibition, addressing challenges in post-translational modification studies.

• Tariquidar (XR9576) in Drug Resistance Research Workflows

  2026-05-12

  Tariquidar (XR9576) delivers targeted, high-fidelity inhibition of P-glycoprotein, enabling reproducible studies of transporter-mediated drug resistance—even in complex, high-viscosity tumor microenvironments. This article bridges mechanobiological insights with actionable protocols, troubleshooting tips, and comparative analysis to empower advanced cancer chemoresistance research.

• Sprayable Hydrogel Nanoparticles for Local Olaparib Delivery

  2026-05-12

  This study introduces a sprayable, bioadhesive hydrogel system embedding polymer-coated nanoparticles of etoposide and Olaparib (AZD2281) for local, post-surgical delivery to glioblastoma. The approach addresses challenges in drug diffusion and blood-brain barrier penetration, offering a new platform for targeted DNA damage response research in brain tumors.

16394 records 1/1093 page Next 12345 下5页 Last page